A recent trend observed in the tissue diagnostics industry is increasing usage of immunohistochemistry products as companion diagnostics devices. Increasing prevalence of cancer has fuelled the demand of better diagnostic techniques, which could detect cancer in the earliest stage. According to the WHO, in 2012, there were 14 million new cancer cases and 8.2 million cancer related deaths worldwide.
The global tissue diagnostics market is categorized on the basis of product type, technology, application, and end-user. Based on product type, the tissue diagnostics market can be categorized as instruments and consumables. On the basis of technology, the tissue diagnostics market is categorized as digital pathology and workflow management, in situ hybridization, immunohistochemistry, and special staining. The immunohistochemistry segment leads the global tissue diagnostics market in terms of market size.
Geographically, North America will be leading the global tissue diagnostics market in the coming years due to high prevalence of cancer cases, high healthcare expenditure, and presence of a large number of hospitals and pharmaceutical companies. Additionally, the legislative reform of Affordable Care Act in the U.S. is also expected to drive the North American market in the coming years.
Asia-Pacific is the fastest growing region in the global tissue diagnostics market. The major reasons for the fastest growth in the region are aging population, increasing disposable income, and improving healthcare infrastructure. Moreover, the tissue diagnostics marketis growing due to large unexplored tissue diagnostics market and large population base suffering with cancer in the emerging economies, such as India and China, of Asia-Pacific region.
Some of the major players operating in the global tissue diagnostics market are F. Hoffmann-La Roche AG., Sigma Aldrich Corporation, Abbott, Biogenex Laboratories, BioSB, Cell Signalling Technology Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, GE Healthcare, and Siemens Healthcare.
The global tissue diagnostics market is categorized on the basis of product type, technology, application, and end-user. Based on product type, the tissue diagnostics market can be categorized as instruments and consumables. On the basis of technology, the tissue diagnostics market is categorized as digital pathology and workflow management, in situ hybridization, immunohistochemistry, and special staining. The immunohistochemistry segment leads the global tissue diagnostics market in terms of market size.
 |
| To Learn More About this report at: http://bit.ly/2Q76du2 |
Asia-Pacific is the fastest growing region in the global tissue diagnostics market. The major reasons for the fastest growth in the region are aging population, increasing disposable income, and improving healthcare infrastructure. Moreover, the tissue diagnostics marketis growing due to large unexplored tissue diagnostics market and large population base suffering with cancer in the emerging economies, such as India and China, of Asia-Pacific region.
Some of the major players operating in the global tissue diagnostics market are F. Hoffmann-La Roche AG., Sigma Aldrich Corporation, Abbott, Biogenex Laboratories, BioSB, Cell Signalling Technology Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, GE Healthcare, and Siemens Healthcare.
